found that ALDH1A1 expression was improved after neoadjuvant chemotherapy in high-grade serous ovarian cancers and that in treatment-naive tumors, ALDH1A1 overexpression was correlated with drug resistance and a reduced duration of survival. Here, ALDH1A1 is linked to ovarian serous adenocarcinoma.